Previous 10 | Next 10 |
There is no worse tyranny than to force a man to pay for what he does not want merely because you think it would be good for him ." - Robert A. Heinlein, The Moon is a Harsh Mistress Today, we revisit Pieris Pharmaceuticals ( PIRS ) as we have not looked in on this intriguing ' Tier 4 '...
The following slide deck was published by Pieris Pharmaceuticals, Inc. in conjunction with this Read more ...
Pieris Pharmaceuticals (NASDAQ: PIRS ) appoints Hitto Kaufmann, Ph.D. as Senior Vice President and Chief Scientific Officer. More news on: Pieris Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
BOSTON, MA / ACCESSWIRE / September 3 , 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today annou...
BOSTON, MA / ACCESSWIRE / August 29, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer and other indicatio...
Pieris Pharmaceuticals, Inc. (PIRS) Q2 2019 Results Conference Call August 1, 2019 8:00 AM ET Company Participants Allan Reine – Chief Financial Officer Steve Yoder – President and Chief Executive Officer Lou Matis – Senior Vice President and Chief Developmen...
Company to Host an Investor Conference Call on Thursday, August 1, 2019 at 8:00 AM EDT BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through ...
BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS ) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, to...
Cellectar Biosciences (NASDAQ: CLRB ) initiated with Buy rating and $6 (180% upside) price target at Brookline Capital. Shares up 8% premarket. More news on: Cellectar Biosciences, Inc., Heat Biologics, Inc., Progenics Pharmaceuticals, Inc., Healthcare stocks news, Stocks on th...
Gainers: NovaBay Pharmaceuticals (NYSEMKT: NBY ) +34% . Medley Management (NYSE: MDLY ) +33% . Pieris Pharmaceuticals (NASDAQ: PIRS ) +24% . Daxor (NYSEMKT: DXR ) +18% . Oasmia Pharmaceutical AB (NASDAQ: OASM ) +17% . Acasti Pharma (NASDAQ: ACST ) +15% . Mylan N.V. (NASDAQ: MYL...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
2024-07-27 03:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...